Journal
NEUROTOXICOLOGY
Volume 43, Issue -, Pages 36-45Publisher
ELSEVIER
DOI: 10.1016/j.neuro.2013.10.003
Keywords
Manganese; Parenteral nutrition; Biomonitoring; Neurotoxicity
Categories
Funding
- FCT (Foundation for Science and Technology of Portugal) [SFRH/BD/64128/2009]
- National Institute of Environmental Health Sciences [ES R01 10563]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/64128/2009] Funding Source: FCT
Ask authors/readers for more resources
The iatrogenic risks associated with excessive Mn administration in parenteral nutrition (PN) patients are well documented. Hypermanganesemia and neurotoxicity are associated with the duration of Mn supplementation, Mn dosage, as well as pathological conditions, such as anemia or cholestasis. Recent PN guidelines recommend the biomonitoring of patients if they receive Mn in their PN longer than 30 days. The data in the literature are conflicting about the method for assessing Mn stores in humans as a definitive biomarker of Mn exposure or induced-neurotoxicity has yet to be identified. The biomonitoring of Mn relies on the analysis of whole blood Mn (WB Mn) levels, which are highly variable among human population and are not strictly correlated with Mn-induced neurotoxicity. Alterations in dopaminergic (DAergic) and catecholaminergic metabolism have been studied as predictive biomarkers of Mn-induced neurotoxicity. Given these limitations, this review addresses various approaches for biomonitoring Mn exposure and neurotoxic risk. (C) 2013 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available